Document is current
Any future updates will be listed below
-
Authors
Allan, Lindsey L.
Skene, Simon S.
Eastley, Kate Bennett
Herbertson, Rebecca
Smith, Eleanor
Michael, Agnieszka
-
Funding
Funding for this research was provided by:
Target Ovarian Cancer (PS-SurreyAM22)
- License Information
-
More Information
Article History
Received: 30 October 2023
Accepted: 1 July 2024
First Online: 2 August 2024
Declarations
:
: Ethical approval was obtained from the Southeast Coast – Surrey Research Ethics Committee (reference 16/LO/2079). The trial was sponsored by Royal Surrey NHS Foundation Trust and was included on the National Institute for Health Research clinical trials portfolio for ovarian cancer.
: Informed consent was obtained from all individual participants included in the study.
: Lindsey Allan has served on advisory boards for Nutricia Ltd., received speaker honoraria from IPSEN, Viatris, Guildford Advanced Courses and financial support for conference attendances from Nutricia Ltd. Agnieszka Michael has received research support from Innovate UK, MERCK and NIHR, honoraria from Pfizer, IPSEN, GSK and Clovis, and served on advisory boards for GSK, Clovis and ESAI.Non-financial interests: Agnieszka Michael has a leadership role at the British Gynaecological Cancer Society.Simon Skene, Eleanor Smith and Rebecca Herbertson declare no competing interests.
